Truist Financial Cuts ICON Public (NASDAQ:ICLR) Price Target to $208.00

ICON Public (NASDAQ:ICLR) had its price objective decreased by Truist Financial from $262.00 to $208.00 in a research note published on Thursday morning,Benzinga reports. Truist Financial currently has a buy rating on the medical research company’s stock.

ICLR has been the topic of several other reports. Barclays dropped their price target on ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a research report on Friday, February 21st. Royal Bank of Canada restated an “outperform” rating and issued a $263.00 price target on shares of ICON Public in a research report on Wednesday, January 15th. Robert W. Baird lowered their price objective on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. JPMorgan Chase & Co. dropped their price objective on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Finally, Citigroup decreased their target price on ICON Public from $290.00 to $215.00 and set a “buy” rating for the company in a research note on Monday, April 7th. Six research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ICON Public currently has a consensus rating of “Moderate Buy” and an average target price of $243.33.

ICON Public Price Performance

Shares of NASDAQ:ICLR opened at $144.04 on Thursday. The stock has a market cap of $11.63 billion, a PE ratio of 15.11, a price-to-earnings-growth ratio of 1.86 and a beta of 1.24. The business’s fifty day moving average price is $179.62 and its two-hundred day moving average price is $210.84. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. ICON Public has a one year low of $138.51 and a one year high of $347.72.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The business had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. On average, analysts forecast that ICON Public will post 13.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ICLR. Sierra Ocean LLC acquired a new stake in ICON Public in the 4th quarter valued at about $29,000. Park Place Capital Corp increased its holdings in shares of ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 166 shares during the period. Private Trust Co. NA lifted its position in shares of ICON Public by 48.8% in the fourth quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after purchasing an additional 82 shares in the last quarter. NBC Securities Inc. purchased a new position in ICON Public during the first quarter valued at approximately $59,000. Finally, GAMMA Investing LLC boosted its stake in shares of ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after buying an additional 169 shares during the period. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.